BSXBOSTON SCIENTIFIC CORPLarge cap · $66.54B · FY ending 2025-12-31
$44.77-0.49% · 2026-07-10 · EOD
69/100 composite
A transparent blend of the four reads below — each opens into the tool it comes from. Not advice.Quality78
narrow moat · ROIC 11%Value78
P/E 23.1 · 3% of 12-mo rangeMomentum21
death · price below 200-daySmart Money98
buying · 1 funds · 3P/0S insidersBearish stackDeath crossBelow 200-day
vs S&P 500-64.1%
6-mo excess Trailing performance1M -8.6%
3M -26.9%
6M -54.6%
YTD -52.7%
1Y -56.5%
P/E vs its last 12 months (our price history): 22.0 low → 55.7 high
Current price sits at the 3th percentile of that window — near the bottom (cheaper). We only compare against the price history we own (no paid multi-year multiples — nothing invented).
Narrow moat — ROIC 11%
Piotroski F8/9
fundamental strength Altman ZSafe
bankruptcy zone ROIC = NOPAT ÷ (debt + equity − cash), using an effective tax rate of 15%. Annual figures from SEC XBRL.
Net buying3P / 0S insiders · 1 funds hold · 4 Congress buys
Recent insidersHabiger David C · DirectorBUY$251,098
LUDWIG EDWARD J · DirectorBUY$202,914
Pegus Cheryl · DirectorBUY$99,987
Fund holders (13F)PRIMECAP Management$2.04B1.6% of book
CongressGilbert CisnerosBUY2026-06-05
Bhealth · 72/100
Self-fundingSelf-funding — profitable · generates cash
No red flags from its filings.
Educational tools — not financial advice. Fundamentals from SEC EDGAR (XBRL); prices are end-of-day (Databento). Scores are a transparent blend of the components shown, computed on our own data — a research aid, not a recommendation.